Amgen announced plans to invest more than $600 million to build a cutting-edge science and innovation center at its global headquarters in Thousand Oaks, California. The facility aims to accelerate drug discovery through advanced automation and digital tools, fostering multi-disciplinary collaboration among researchers and engineers. Construction is slated to begin in Q3 2025, with the project expected to create hundreds of jobs. This investment builds on Amgen’s recent $900 million manufacturing expansion and a $1 billion plant in North Carolina. The company cites recent US pro-growth tax policies as enabling its substantial domestic investments in biotech manufacturing and research.